Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 8 September 2015, 18:52 HKT/SGT
Share:
    

Source: Uni-Bio Science Group Limited
Uni-Bio Science Group's Chemical Manufacturing Line in Beijing Passes GMP 2010 Standard

HONG KONG, Sept 8, 2015 - (ACN Newswire) - Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) is pleased to announce that the Group's chemical manufacturing line in Beijing has successfully passed the inspection under "Good Manufacturing Practice (2010 revision)"("GMP 2010") and received the Certificate of GMP for pharmaceutical products issued by China Food and Drug Administration ("CFDA") on 17 August 2015.

Mr. Kingsley LEUNG, Executive Director of Uni-Bio Science, said, "Upgrading to the latest GMP manufacturing standard will provide a number of advantages to the Group, including ensuring freedom to operate, improving product quality and upgrading manufacturing capacity, etc. In addition, we believe the upgrade will provide opportunities for the Group to acquire additional drug licenses to strengthen its competitive position in the industry."

It is a requirement by the CFDA for all industry participants to upgrade their manufacturing facilities to meet the new GMP 2010 standards by the end of 2015. The new standards closely mirror the standards of the European Medicines Agency. Together with the Group's Shenzhen facility, which has already achieved the GMP 2010 certification in 2013, all of the Group's manufacturing lines are new GMP ready. This achievement is an assertion of the Group's strength in producing high quality drugs, ensuring efficacious and safe products for our patients.


Contact:
Strategic Financial Relations Limited
Veron Ng     Phone: +852 2864 4831   Email: veron.ng@sprg.com.hk
Angelus Lau  Phone: +852 2864 4805   Email: angelus.lau@sprg.com.hk
Caley Chan   Phone: +852 2114 4950   Email: caley.chan@sprg.com.hk
Fax:   +852 2527 1196



Topic: Press release summary
Source: Uni-Bio Science Group Limited

Sectors: Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Uni-Bio Science Group Limited
July 19, 2017 08:23 HKT/SGT
HeungKong Great Health Fund I Injects HK$120 Million into Uni-Bio Science and Becomes its Strategic Shareholder
Feb 27, 2017 09:10 HKT/SGT
Uni-Bio Science's Drugs Officially Reimbursed under the National Reimbursement Drug List
Aug 26, 2016 20:14 HKT/SGT
Uni-Bio Science Group Announces 2016 Interim Results
June 27, 2016 21:06 HKT/SGT
Uni-Bio Science Group Forges Strategic Alliance with China Resources Zizhu for GeneSoft
June 14, 2016 08:06 HKT/SGT
Uni-Bio Science Group Announces 2015 Annual Results
Mar 8, 2016 19:24 HKT/SGT
Uni-Bio Science Completes Phase I Single Ascending Dose (SAD) Tolerability Study of Uni-EPO-Fc for Treatment of Anaemia
Nov 24, 2015 22:55 HKT/SGT
Uni-Bio Science Acquires Global Rights to Type 2 Diabetes Drug Mitiglinide from Jiangsu Hansoh Pharmaceutical Co. Ltd
Aug 14, 2015 22:00 HKT/SGT
Uni-Bio Science Group Announces 2015 Interim Results
Aug 3, 2015 10:20 HKT/SGT
Uni-Bio Science Group Announces Positive Phase III Results for Uni-E4 in Type-2 Diabetes
July 16, 2015 19:13 HKT/SGT
Uni-Bio Science Group Garners "Pharmaceuticals Award" for Best Innovation at Hong Kong Business Listed Companies Awards
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: